Variation in NGFB is associated with primary affective disorders in women

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
American Journal of Medical Genetics Part B Neuropsychiatric Genetics (Impact Factor: 3.27). 06/2011; 156B(4):401-12. DOI: 10.1002/ajmg.b.31175
Source: PubMed

ABSTRACT Affective disorders (AFDs) are highly comorbid with substance dependence (SD) and both are genetically influenced. However, the specific etiology of the comorbidity is not well understood. We genotyped an array of 1,350 single nucleotide polymorphisms (SNPs) in or near 130 genes in 868 European-Americans (EAs), including 182 individuals with primary AFDs (PAFDs), 214 with SD comorbid with AFD (CAFD), and 472 screened controls. NGFB, which encodes nerve growth factor β and was represented in the array by 15 SNPs, showed the strongest evidence of association, but only among women with PAFDs. Six of the SNPs showed nominally significant association with PAFDs in women (P's = 0.0007-0.01); three (rs2856813, rs4332358, and rs10776799) were empirically significant based on 1,000,000 permutations (P's = 0.008-0.015). Seven haplotypes were significantly associated with PAFDs in women (P's = 0.0014-0.01), of which six were significant based on empirical permutation analysis (minimal P = 0.0045). Four diplotypes were significantly associated with PAFDs in women (global P's = 0.001-0.01). The specific diplotype GG-TC, reconstructed from rs2856813 and rs6678788, showed the strongest evidence of association with PAFDs in women (OR = 4.07, P = 4.2E-05). No SNPs or haplotypes were associated with PAFDs in men or with CAFDs in either sex. We conclude that variation in NGFB is a risk factor for PAFDs in women, but not for CAFD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This narrative review aims to provide an overview of the impact of opioid dependence and the contribution of genetics to opioid dependence. Epidemiological data demonstrate that opioid dependence is a global trend with far-reaching effects on the social, economic, and health care systems. A review of classical genetic studies of opioid use suggests significant heritability of drug use behavior, however the evidence from molecular genetic studies is inconclusive. Nonetheless, certain genetic variants are important to consider given their role in the pathophysiology of addictive behavior. We undertook a literature review to identify the current state of knowledge regarding the role of genes in opioid dependence. Determining the association of genetic markers could change the current understanding of the various factors contributing to opioid dependence and therefore may improve recognition of individuals at risk for the disorder and prevention and treatment strategies.
    Current Psychiatry Reviews 05/2014; 10(2):141-152. DOI:10.2174/1573400510666140320000928
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Considerable variation is evident in response to psychological therapies for mood and anxiety disorders. Genetic factors alongside environmental variables and gene-environment interactions are implicated in the etiology of these disorders and it is plausible that these same factors may also be important in predicting individual differences in response to psychological treatment. In this article, we review the evidence that genetic variation influences psychological treatment outcomes with a primary focus on mood and anxiety disorders. Unlike most past work, which has considered prediction of response to pharmacotherapy, this article reviews recent work in the field of therapygenetics, namely the role of genes in psychological treatment response. As this is a field in its infancy, methodological recommendations are made and opportunities for future research are identified.
    02/2013; 3(1):4. DOI:10.1186/2045-5380-3-4
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal neurodevelopmental processes are found in the brains of schizophrenia patients. Nerve growth factor (beta polypeptide) (NGF) is known to play a major role in neuronal growth, differentiation, and neuroprotection of the brain. To investigate whether NGF polymorphisms are associated with schizophrenia patients, eight single nucleotide polymorphisms (SNPs; rs10776800, rs11102924, rs4839435, rs12760036, rs11102919, rs11466098, rs2268793, and rs6330) of the NGF were selected and genotyped by direct sequencing in 217 schizophrenia patients and 378 control subjects. SNPAnalyzer, SNPStats, and Haploview version 4.2 were used to analyze the genetic data. Multiple logistic regression models (codominant1, codominant2, dominant, recessive, overdominant, and log-additive) were performed to calculate odds ratios (ORs), 95% confidence intervals (CIs), and P values. P values (P c ) were recalculated using Bonferroni correction to better define results. It was found that the allele frequency of rs12760036 SNP of the NGF was associated with the susceptibility to schizophrenia (P c =0.0016, OR=1.65, 95% CI=1.27–2.15). Genotype frequency of rs12760036 of the NGF was also associated with schizophrenia patients (P c =0.0024, OR= 1.90, 95% CI=1.34–2.71). In the linkage disequilibrium block between rs12760036 and rs4839435, the AG and CA haplotype frequencies between schizophrenia patients and the control group were significantly different (P=0.0002; P=0.0033, respectively). These results suggest that the rs12760036 may be a risk factor to the susceptibility of schizophrenia in Korean population.
    Molecular and Cellular Toxicology 12/2012; 7(4). DOI:10.1007/s13273-011-0047-4 · 0.83 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014